A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE

Beckman Symposium

The 23rd Beckman Symposium - Antibody Engineering
Friday, December 6, 2013
8:30 a.m. to 5 p.m.

City of Hope
Cooper Auditorium
1500 E. Duarte Road
Duarte, CA 91010-3000

The 23rd Beckman Symposium to be held at Beckman Research Institute of City of Hope. Supported by funds from the Beckman Endowment, the Beckman Symposia are arranged annually by the research staff organization of City of Hope.
2013 Speaker List:
Patrick A. Baeuerle, Ph.D.
Amgen Research, Munich, Germany
Shmuel Cabilly, Ph.D.
High Tech Investor and Board Member
Paul Carter, Ph.D.
Herbert A. Heynecker, Ph.D.
Advisor, Thuja Capital
Andreas Plückthun, Ph.D.
University of Zurich, Switzerland
Arthur D. Riggs, Ph.D.
City of Hope
Peter Senter, Ph.D.
Seattle Genetics, Inc.
E. Sally Ward, Ph.D.
University of Texas Southwestern Medical Center, Dallas
Anna Wu, Ph.D.
University of California, Los Angeles


In compliance with the Americans with Disabilities Act, all reasonable efforts will be made to accommodate persons with disabilities at the meeting. If you have any special dietary or accommodation needs, please notify the program coordinator listed above prior to the symposium. This advance notification will help us serve you better.


Symposium Program

8:30 to 9 a.m.

9 to 9:10 a.m.
David Horne, Ph.D.
Interim Director, Beckman Research Institute
City of Hope
9:10 to 9:20 a.m.
Overview of Morning Session
John E. Shively, Ph.D.
City of Hope
9:20 to 10:10 a.m.
Early Recombinant Antibody Studies at City of Hope and Genentech
Arthur D. Riggs, Ph.D., City of Hope
Shmuel Cabilly, Ph.D., High Tech Investor and
Board Member Herbert Heynecker, Ph.D., Advisor, Thuja Capital
10:10 to 10:30 a.m.
10:30 to 11:20 a.m.
Engineered Antibodies for Molecular Imaging in Oncology and Beyond
Anna Wu, Ph.D., University of California
Los Angeles
11:20 a.m. to 12:10 p.m.
From Knobs-into-Holes to Onartuzumab
Paul Carter, Ph.D., Genentech
12:10 to 1:10 p.m.
1:10 to 1:20 p.m.
Overview of Afternoon Session
Andrew Raubitschek, M.D.
City of Hope
1:20 to 2:10 p.m.
Combinatorial and Evolutionary Engineering:
The Binders and Targets
Andreas Plückthun, Ph.D.
University of Zurich, Switzerland
2:10 to 3 p.m.
Targeting FcRn for Therapy
Sally Ward, Ph.D.
University of Texas Southwestern Medical Center, Dallas
3 to 3:20 p.m.
3:20 to 4:10 p.m.
Empowered Antibodies for Cancer Therapy
Peter Senter, Ph.D.
Seattle Genetics, Inc.
4:10 to 5 p.m.
Cancer Therapy by T Cell-engaging
Bispecific Antibodies
Patrick Baeuerle, Ph.D., Amgen Research,
Munich, Germany


*Registration and lunches are limited to the first 350 registrants*
Research Overview
Research pioneered at City of Hope has improved the lives of men, women and children throughout the world.
Recognized as one of the nation’s premier centers for innovative biomedical research, City of Hope’s Beckman Research Institute advances the fundamental understanding of molecular genetics, cellular biology and more.
Our City of Hope's Comprehensive Cancer Center provides a multidisciplinary, interactive environment where basic, clinical and translational scientists collaborate closely.
Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.

City of Hope offers a number of exciting fellowships and residencies in laboratory research, administration, clinical applications and other areas.
Technology & Licensing
The Center for Applied Technology Development offers broad expertise in technology transfer and licensing, biologics manufacturing, quality assurance and regulatory affairs.

  • For breast cancer survivors, a common worry is a recurrence of their cancer. Currently, these patients are screened with regular mammograms, but there’s no way to tell who is more likely to have a recurrence and who is fully cleared of her cancer. A new blood test – reported in Cancer Research, a journal of the...
  • Metastasis — the spreading of cancer cells from a primary tumor site to other parts of the body — generally leads to poorer outcomes for patients, so oncologists and researchers are constantly seeking new ways to detect and thwart this malicious process. Now City of Hope researchers may have identified a substa...
  • Deodorant, plastic bottles, grilled foods, artificial sweeteners, soy products … Do any of these products really cause cancer? With so many cancer myths and urban legends out there, why not ask the experts? They can debunk cancer myths while sharing cancer facts that matter, such as risk factors, preventi...
  • Cancer risk varies by ethnicity, as does the risk of cancer-related death. But the size of those differences can be surprising, highlighting the health disparities that exist among various ethnic groups in the United States. Both cancer incidence and death rates for men are highest among African-Americans, acco...
  • George Winston, known worldwide for his impressionistic, genre-defying music, considers music to be his first language, and admits he often stumbles over words – especially when he attempts languages other than English. There’s one German phrase he’s determined to perfect, however: danke schön. Winston thinks h...
  • Few decisions are more important than those involving health care, and few decisions can have such lasting impact, not only on oneself but on relatives and loved ones. Those choices, especially, should be made in advance – carefully, deliberately, free of pain and stress, and with much weighing of values and pr...
  • Using a card game to make decisions about health care, especially as those decisions relate to the end of life, would seem to be a poor idea. It isn’t. The GoWish Game makes those overwhelming, but all-important decisions not just easy, but natural. On each card of the 36-card deck is listed what seriously ill,...
  • Young adults and adolescents with cancer face unique challenges both during their treatment and afterward. Not only are therapies for children and older adults not always appropriate for them, they also must come to terms with the disease and treatment’s impact on their relationships, finances, school or ...
  • Breast cancer is the most common cancer, other than skin cancer, among women in the United States. It’s also the second-leading cause of cancer death, behind lung cancer. In the past several years, various task force recommendations and studies have questioned the benefits of broad screening guidelines fo...
  • Paternal age and the health effects it has on potential offspring have been the focus of many studies, but few have examined the effect parental age has on the risk of adult-onset hormone-related cancers (breast cancer, ovarian cancer and endometrial cancer). A team of City of Hope researchers, lead by Yani Lu,...
  • Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal h...
  • Myeloproliferative neoplasms can’t be narrowed down to a single cancer, but they can be described by a defining characteristic: too many blood cells. The diseases bring with them a host of frustrating, potentially life-altering symptoms, and management of the diseases and their symptoms is crucial. An upcoming ...
  • More than 18,000 researchers, clinicians, advocates and other professionals will convene at the 105th American Association for Cancer Research (AACR) annual meeting taking place in San Diego from April 5 to 9. With more than 6,000 findings being presented over this five-day period, the amount of information can...
  • Cancer of the prostate is the No. 2 cancer killer of men, behind lung cancer, accounting for more than 29,000 deaths annually in this country. But because prostate cancer advances slowly, good prostate health and early detection can make all the difference. Many prostate cancer tumors don’t require immedi...
  • Despite advances made in detecting and treating nonsmall cell lung cancer, its prognosis remains grim. Even patients whose cancers are caught at their earliest stage have only a 50 percent chance of five-year survival. This poor prognosis is due in part to the cancer’s ability to resist treatment, renderi...